For someone who has been tracking their tirzepatide weight loss timeline and watching progress slow, those numbers are hard to ignore
As we have been hammering quite hard, the key to unlocking real GLP-1 secondary effects and the massive 100M US market for effective weight loss drugs to combat the obesity epidemic is dual pronged , involving: Increased Insurance Coverage Effective Oral Preparation That aspect is the same as it has always been, so lets go ahead and see if were any closer to either of them These two factors work hand in hand to ultimately result in a cheaper alternative that is significantly less supply constrained and sees wider adoption
Could a Nobel be next?', STAT News
Test subjects with a history of cancer are typically excluded from studies involving GH secretagoguges due to concerns that elevated GH levels could affect the progression of cancer
The prevalence of NAFLD has increased rapidly over the last two decades, in parallel with the dramatic rise in obesity and diabetes
In late 2023, the FDA also approved it for chronic weight management for people with obesity (body mass index of 30 kg/m 2 or higher) or overweight (body mass index of 27-29 kg/m 2 ) and at least one weight-related health condition, such as high blood pressure, Type 2 diabetes or high cholesterol